![Martijn Franssen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Martijn Franssen
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Rabo Private Equity
![]() Rabo Private Equity Investment ManagersFinance Rabo Private Equity (RPE) is the private equity arm of the Rabobank Group and is headquartered in Utrecht. RPE originated in 1972 following the merger of two separate Dutch cooperative banks, the Cooperatieve Centrale Raiffeisen-Boerenleenbank in Utrecht and the Cooperatieve Centrale Boerenleenbank in Eindhoven. The firm was formally established in 1998. RPE is based in Utrecht and operates through two separate entities, Rabo Participaties and Rabo Capital.
11
| Subsidiary | Investment Managers | 11 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Martijn Franssen
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
O2 Capital Partners BV
![]() O2 Capital Partners BV Investment ManagersFinance O2 Capital Partners (O2 Capital) is a private equity and venture capital firm founded in 2011 by Philip Sluiter, Bob van der Veen and Pieter van der Zanden. The firm headquartered in Oosterbeek, Netharlands. | Investment Managers | Founder Founder | |
Arlon Capital Partners Management Co. LLC
![]() Arlon Capital Partners Management Co. LLC Investment ManagersFinance Arlon Capital Partners Management Co. LLC (Arlon Capital Partners) is a private equity firm subsidiary of Arlon Group LLC founded in 2007. The firm is is headquartered in New York. | Investment Managers | Private Equity Investor | |
Erasmus University Rotterdam | College/University | Graduate Degree | |
IBS Capital Management BV
![]() IBS Capital Management BV Investment ManagersFinance IBS Capital Management BV is an alternative investment manager based in the Netherlands. The Dutch company acts as an investment manager for alternative investments. Harold Knebel has been the CEO of the private company since 2016. | Investment Managers | Private Equity Investor | |
KplusV Startgreen Investment Services BV
![]() KplusV Startgreen Investment Services BV Investment ManagersFinance KplusV Startgreen Investment Services BV is an independent private equity firm with its headquarters in Amsterdam, the Netherlands. It was founded in 2013. | Investment Managers | Private Equity Investor | |
Nordian Capital BV
![]() Nordian Capital BV Investment ManagersFinance Nordian Capital BV(Nordian Capital), formerly known as Rabo Capital an independent Netherlands based private equity firm which was founded in September 2014 as a spinoff from Rabobank. | Investment Managers | Private Equity Investor | |
Victus Participations BV
![]() Victus Participations BV Investment ManagersFinance Victus Participations BV is an Independent Private Equity firm founded in 2017. Victus Participations BV is headquartered in Amsterdam. | Investment Managers | Founder | |
De Gentse Kluis NV
![]() De Gentse Kluis NV Food: Specialty/CandyConsumer Non-Durables De Gentse Kluis SA engages in the supply of frozen ready to eat meals. The company was founded on July 5, 2006 and is headquartered in Veurne, Belgium. | Food: Specialty/Candy | Director/Board Member | |
Biogeneration Management BV
![]() Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Investment Managers | Private Equity Investor | |
Dualyx NV
![]() Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Chief Executive Officer | |
Nimbus Control BV
![]() Nimbus Control BV Investment ManagersFinance Nimbus Control BV (Nimbus) is an independent investment firm with headquarters in the Netherlands. Nimbus was founded in 1993 and has offices located in Munich, Germany and Brussels, Belgium. | Investment Managers | Private Equity Investor |
Statistik
International
Niederlande | 10 |
Belgien | 3 |
Vereinigte Staaten | 2 |
Sektoral
Finance | 10 |
Consumer Services | 2 |
Consumer Non-Durables | 2 |
Commercial Services | 2 |
Operativ
Private Equity Investor | 20 |
Founder | 3 |
Graduate Degree | 1 |
Director/Board Member | 1 |
Private Equity Analyst | 1 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Martijn Franssen
- Unternehmensverbindungen